Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial

BACKGROUND: The proteasome inhibitor bortezomib sensitizes tumor cells to chemotherapy-induced apoptosis. In preclinical non–small-cell lung cancer (NSCLC) models, p53-dependent growth arrest after bortezomib treatment resulted in reduced cytotoxicity if bortezomib preceded docetaxel. The reverse se...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lara, Primo N., Longmate, Jeff, Reckamp, Karen, Gitlitz, Barbara, Argiris, Athanassios, Ramalingam, Suresh, Belani, Chandra P., Mack, Philip C., Lau, Derick H. M., Koczywas, Mariana, Wright, John J., Shepherd, Frances A., Leighl, Natasha, Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3777729/
https://ncbi.nlm.nih.gov/pubmed/21273177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLC.2011.n.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares